| Literature DB >> 12040309 |
Douglas W Scharre1, Shu-Ing Chang.
Abstract
In a prospective, open-label, 12-week pilot study in outpatients with probable Alzheimer disease (AD) with psychosis or aggressive behaviors, we used the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog) and the Neuropsychiatric Inventory (NPI) to evaluate the cognitive and behavioral effects of quetiapine. After receiving doses ranging from 50 to 150 mg, patients given quetiapine showed a significant decrease of delusions, aggression, and overall behaviors based on NPI scores at 6 and 12 weeks. ADAS-cog scores did not show a significant change over 12 weeks. This study provides initial evidence that quetiapine does not significantly worsen cognition in AD outpatients.Entities:
Mesh：
Substances：
Year: 2002 PMID： 12040309 DOI： 10.1097/00002093-200204000-00011
Source DB: PubMed Journal: Alzheimer Dis Assoc Disord ISSN： 0893-0341 Impact factor: 2.703